Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy
- Conditions
- Fibroid Uterus
- Interventions
- Registration Number
- NCT04272086
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Brief Summary
The study team will be randomizing patients presenting for open myomectomy to either received transversus abdominal plane blocks with either liposomal bupivacaine or standard bupivacaine. The study team will be analyzing the impact of local anesthetic on opiate consumption as the investigator's primary endpoint with other secondary endpoints.
- Detailed Description
After consent, patients will be randomized to either liposomal bupivacaine Transversus Abdominal Plane (TAP) vs standard bupivacaine TAP. Blocks will occur post induction and pre incision. Only the block team (not the anesthesia team nor the care team) will be unblinded and they will not have any impact on the data collection. The entire care team and the patient will be blinded. A standardized anesthetic regimen will be employed followed by a prescriptive post-operative pain management plan aimed at enhanced recovery. Patients will be followed for up to 96 hours and asked about their opiate consumption, pain scores, side effects, and recovery.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 140
- Not pregnant
- Weight over 50kg presenting for open myomectomy
- No history of allergy to any study medication
- No history of malignant ventricular dysrhythmia, epilepsy, seizure disorder, or chronic pain syndrome other than pain from myomas
- No history of drug or alcohol use or abuse disorder or pre-existing liver disease.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Liposomal bupivacaine TAP Bupivacaine liposome TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side Bupivacaine TAP normal saline TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side Liposomal bupivacaine TAP normal saline TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side Liposomal bupivacaine TAP Bupivacaine TAP block with 10mL liposomal bupivacaine, 20mL 0.25% bupivacaine, and 10mL normal saline for a total of 40 mL per side Bupivacaine TAP Bupivacaine TAP block with 30 mL 0.25% bupivacaine mixed with 10 mL normal saline for a total of 40 mL per side
- Primary Outcome Measures
Name Time Method Morphine Equivalents at 72 Hours 72 hours Total cumulative opiates consumed converted to morphine equivalents
- Secondary Outcome Measures
Name Time Method Area under the curve pain scale at 96 hours 96 hours Sum of pain scores at 24, 48, 72, and 96 hours. Pain scale from 0-10, with higher score indicating worst pain.
Quality of Recovery at 48 hours 48 hours 15 question quality of recovery scale, full scale from 0-150, with lower score indicating better recovery.
Morphine Equivalents at 96 Hours 96 hours Total cumulative opiates consumed converted to morphine equivalents
Morphine Equivalents at 48 Hours 48 hours Total cumulative opiates consumed converted to morphine equivalents
Opiate Sparing Criteria at 72 hours 72 hours Composite score of minimal opiate dose and additionally scores of 0 on questions 2,3,4,5,6 on OBAS scoring scale.
Overall Benefit of Analgesic Score (OBAS) scoring scale -total scale from 0-20, low score indicates high benefit.Quality of Recovery at 72 hours 72 hours 15 question quality of recovery scale, full scale from 0-150, with lower score indicating better recovery.
Trial Locations
- Locations (1)
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States